Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Oncology Markets
- Therapeutic Cancer Antibodies
- Antibodies Already on the Market
- Antibodies in Late-Stage Development
- Cancer Vaccines
- Vaccine Technologies
- Clinical Development Pipeline
- Industry-Shaping Events
- Combination MAb Therapies Not As Obvious As Hoped
- Some Cancer Vaccine Companies on the Brink
- Recent Deals and Business Strategies
- Antibody-Based Dealmaking
- Lilly' s Acquisition of ImClone Systems
- Roche' s Hostile Takeover of Genentech
- Merck & Co.' s Planned Merger with Schering-Plough
- Cancer Vaccine Dealmaking
- GlaxoSmithKline and Innogenetics
- Pfi zer and Celldex Therapeutics
- Merck Serono and Oncothyreon
- Takeda and Cell Genesys
- Oxford BioMedica and Sanofi -Aventis
- Transgene and Roche
- Market Drivers - MAb-Based Immunotherapies
- Additional Indications
- Shifts to Earlier-Stage Disease
- Biomarkers
- Biosimilars
- Cost
- Combination Targeted Therapies
- Market Drivers - Cancer Vaccines
- Outlook
Tables
- 1. Marketed Antibody Therapies for Oncology
- 2. Select Antibody Therapies in Phase II or Phase III Development for
Oncology
- 3. Cancer Vaccines in Phase III Development or Later
- 4. Select Combination Targeted Therapies in Development, 2008
- 5. Dealmaking: Cancer Monoclonal Antibodies, 2007 and 2008
- 6. Dealmaking: Select Cancer Vaccines, 2008
- 7. Dealmaking: Biomarkers Driving the Development and Sale of Targeted
Cancer Therapies, 2008
- 8. Potential Biosimilar Entry Dates for Marketed Monoclonal Antibody-Based
Immunotherapies
- 9. Cost Comparison of Targeted Therapy Cancer Treatment in the Adjuvant
and Advanced-Stage Settings
Figures
- 1. Forecasted Growth Rate for the Oncology Market, 2007-2014
- 2. Top Ten Companies in the Oncology Market, 2007 and 2014
- 3. Targeted Monoclonal Antibody Therapies: Combined Treatment in
Metastatic Colorectal Cancer
- 4. Commercial Potential of Treating Early-Stage and Late-Stage Cancer
|
Related Report
|
View Cart
